Skip to main content

EventTrader

AI-Native Trading
PAPER
Menu
Tuatara Hedge Fund Fund Builder Revenue Share Event Cards Tradable Headlines Leaderboard AI Apps Exchange
Account
Profile Balances Transactions Fund Application Flows
Trade
Home FTA Fund AI MicroFund AI Hedge Fund Prop Desk ACI Challenge Launch a Token
Agents
AI Bots (Blue Team) AI Bots (Red Team) AgentBook My Agents Marketplace Algos, Data & Models Skills & Tools Backtest
Leaderboards
72h Card Performance Card Rankings Top Traders Feature Voting
Compete
Arena The Track Competitions Exchange Votes
Community
Revenue Share Rewards
Explore
Satellite Intelligence Tools Directory
Learn
ET10 Token (60s) Arena (60s) ETLP Token (60s) API Enterprise AI Consulting Careers Press
Plain English Mode
PAPER TRADING MODE — Enable real trading on your Account page
Back

AI Analyst Report — MTLS × Apollo Global Management / DePuy Synthes (Johnson & Johnson)

EventTrader M&A Ripple desk · generated 2026-09-14 14:15 UTC · report for deal #909 / MTLS
Position MTLS (long)
Deal #909 — Apollo Global Management → DePuy Synthes (Johnson & Johnson)
Reported 2026-09-14 · $20.0B · ma_wire_rt tier R
Entry 2026-09-14T13:35+00:00 UTC · avg 7.5969
Engine leg rank 1 / 25 · score 830.083 · is_direct 1.0
Strategy label overbought z+0.59 · hold window 8 trading days · 100.0% of the deal allocation
Last mark 7.68 (2026-09-14T14:05+00:00 UTC) · +1.09% vs entry
Status open

1. Executive summary

  • Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's DePuy Synthes orthopedics business for around $20 billion, according to The Wall Street Journal; the discussions are ongoing and are not a signed deal [S1].
  • The platform holds a ripple position in Materialise NV (MTLS), which the deal article's engine ranking placed at rank 1 with a score of 830.083 and a direct-mention flag of 1.0 [S2].
  • The strongest documented link is Materialise's own 20-F, which states it "entered into collaborations with DePuy Synthes Companies of Johnson & Johnson, or DePuy Synthes," in the medical market [S4].
  • The main risk is that this is a reported negotiation that may not close, that other buyers could emerge, and that the named Materialise–DePuy Synthes collaboration carries contract expiration dates between March 2026 and September 2027 [S1][S4].
  • The position was entered on 2026-09-14 with a strategy hold window of 8 days, so the thesis is short-dated relative to a separation JNJ initially targeted for completion within roughly 18 to 24 months [S12][S1].

2. The deal

Apollo Global Management is in negotiations to acquire Johnson & Johnson's DePuy Synthes orthopedics business in a transaction valued at around $20 billion, according to The Wall Street Journal as relayed by the deal wire [S1]. The article states plainly that "the discussions remain ongoing, and there is no guarantee they will result in a transaction," and that other potential buyers could still emerge as JNJ evaluates alternatives — this is reportedly in talks, not a signed deal [S1]. DePuy Synthes makes hip, knee and shoulder implants, surgical instruments and other orthopedic technologies, and the business generated approximately $9.3 billion in sales during 2025 [S1].

The seller's own filings corroborate the backdrop. JNJ's 10-K states that in October 2025 the company announced its intention to separate its Orthopaedics business, to be named DePuy Synthes, and that $1.7 billion of trademarks associated with the DePuy Synthes brand were reclassified from definite-lived to indefinite-lived in connection with that decision [S10]. The 10-K reports Orthopaedics sales of $9,258 million versus $9,158 million the prior year, broken into Hips ($1,674M), Knees ($1,587M), Trauma ($3,146M) and Spine, Sports & Other ($2,852M) [S10]. JNJ lists the ability to consummate and successfully separate the Orthopaedics business, and the structure of that separation, among its risk factors [S10]. The deal wire adds that a sale to Apollo would be an alternative to spinning DePuy Synthes into an independent public company [S1].

3. What the engine saw

On the deal article, the Tuatara vector engine (asset_deep_discovery, nasdaq-v08) returned 25 results and ranked MTLS at rank 1 with a score of 830.083 and is_direct = 1.0 [S2]. The seed terms were "materialise," "nv," "3d," "printing," "aided," "johnson," "manufacturing," "spa," "leuven" and "functionality," and the URL's extracted keywords included "johnson," "apollo," "depuy," "synthes," "business," "billion," "acquire" and "transaction" [S2]. MTLS's score dominates the ranking: the next candidate, DDD, scores 42.467, followed by ALGN (21.639, is_direct 0.0), SSYS (19.719, is_direct 1.0), BEGS (17.455, is_direct 1.0), CODA (13.332), PTC (12.245), KLAC (12.166), ADSK (10.471), ACTG (9.262), DDDX (8.489) and SANM (7.846) [S2]. The strategy attached a MACD label of "overbought z+0.59" and a hold window of 8 days to the MTLS leg [S12].

4. The company

MTLS is Materialise NV, described in its 20-F as "a leading provider of additive manufacturing and medical software tools and of sophisticated 3D printing services" [S4]. The Yahoo Finance profile [S3] was not served to this host, so this section relies on the annual report. As of December 31, 2025 the team consisted of 2,556 full-time-equivalent employees, and the intellectual-property portfolio featured 529 granted patents and 128 pending patent applications [S4]. For the year ended December 31, 2025 Materialise generated €267.6 million of revenue, a 0.3% increase, with net profit of €7.7 million, Adjusted EBIT of €10.6 million and Adjusted EBITDA of €32.4 million [S4]. The business is built on three core competencies — software development, 3D printing, and engineering for 3D printing — and its customers span healthcare, automotive, aerospace, art and design and consumer products [S4]. Its most direct additive-manufacturing applications include orthopedic devices, cranio-maxillo-facial devices, eyewear and footwear [S4]. The company reports through three segments — Materialise Medical, Materialise Software and Materialise Manufacturing [S7].

5. Connect the dots

  1. The deal names Johnson & Johnson's DePuy Synthes orthopedics business as the asset Apollo is reportedly pursuing [S1]. Materialise's applications include orthopedic devices, placing it in the same clinical field as the business being sold [S4].

  2. Materialise's 20-F names the counterparty directly: "In the medical market, we have entered into collaborations with DePuy Synthes Companies of Johnson & Johnson, or DePuy Synthes, and Zimmer Biomet Holdings, Inc. ... the expiration dates of which (unless renewed in accordance with our past practice) vary between March 2026 and September 2027" [S4]. This is the specific, documented link between MTLS and the deal target.

  3. The same filing places DePuy Synthes among Materialise's jointly-developed-IP relationships: "We have entered into collaborations with a number of industrial and medical-device companies ... including Zimmer Biomet, Enovis, DePuy Synthes, Lima, Mathys, Siemens, and HP," where "certain intellectual-property developed jointly ... may be subject to joint ownership" and Materialise's commercial use "may be restricted, or may require written consent from ... the partner" [S4].

  4. The engine independently surfaced this relationship: MTLS carries is_direct = 1.0 on the deal article and the seeds include both "materialise" and "johnson" [S2]. The chain therefore runs deal target (DePuy Synthes) → named Materialise collaborator → ripple position (MTLS) [S1][S4][S2].

6. What a change of control could mean

The concrete mechanism is the named collaboration itself. Materialise's 20-F states the DePuy Synthes collaboration has expiration dates that "vary between March 2026 and September 2027" unless renewed in accordance with past practice [S4]. A change of control at DePuy Synthes lands inside that renewal window, which could cut either way: a new owner could renew or deepen the relationship, or could review and not renew it. The filing also flags that increased adoption of Materialise's software, products and services "will depend in part on our current and future collaborators' willingness to continue to adopt" the technology [S4] — so adoption programmes and channel access through DePuy Synthes are a lever a new owner controls.

Jointly developed IP is a second mechanism: because commercial use of that IP "may be restricted, or may require written consent from ... the partner," a new controlling owner of DePuy Synthes would inherit those consent rights [S4]. On the acquirer side, Apollo's 10-K describes an equity strategy of "working with the management teams of the portfolio companies ... to help transform and grow their businesses," with "creative structuring" and "purchase price discipline" [S11]. That operating approach could favour continuity where the collaboration adds value, or restructuring where it does not; the filings reviewed do not state Apollo's intentions for any Materialise contract.

7. Other candidates on the same ranking

Below MTLS, the ranking is populated by additive-manufacturing, 3D-printing and design-software names: DDD (rank 2, 42.467, is_direct 1.0), SSYS (rank 4, 19.719, is_direct 1.0), BEGS (rank 5, 17.455, is_direct 1.0) and DDDX (rank 11, 8.489), alongside ALGN (rank 3), CODA (rank 6), PTC (rank 7), KLAC (rank 8), ADSK (rank 9), ACTG (rank 10) and SANM (rank 12) [S2]. What they share is exposure to 3D printing, medical devices or design/manufacturing software — the same thematic cluster the seeds "3d," "printing," "aided," "manufacturing" and "functionality" describe [S2]. The strategy's weight went to MTLS because its score of 830.083 is roughly twenty times the next candidate's 42.467 and it carries a direct-mention flag, and the recorded allocation shows MTLS as the sole leg on this deal, carrying 100% of the deal allocation [S2][S12].

8. Risks and what breaks the thesis

Deal risk is first-order: the transaction is reported as ongoing talks with "no guarantee they will result in a transaction," other buyers could emerge, and JNJ could still choose a spin-off instead of a sale [S1]. Contract-renewal risk is specific and dated — the Materialise–DePuy Synthes collaboration expires somewhere between March 2026 and September 2027 absent renewal [S4]. On the company's own latest current reports, Materialise announced an ADS Buyback Program in press releases dated August 27, August 28 and September 7, 2026 [S8][S6][S5], and reported second-quarter 2026 total revenue up 8.1% to €70,073 thousand, with the Medical segment up 12.2%, Manufacturing up 6.7% and Software down 2.7% [S7]. Market and technical risk is flagged by the strategy's own MACD label of "overbought z+0.59" [S12]. The strategy's exit rules also break the thesis mechanically: it sells "on the first pass of the trading day strictly after entry + hold_days," an 8-day window from the 2026-09-14 entry, with an 8% deal and component stop-loss and a trailing stop that arms at 3% and trails by 5% [S12].

9. Watch list

  • A definitive agreement or JNJ 8-K confirming or ending the reported Apollo talks, or naming a rival bidder [S1].
  • Completion of the DePuy Synthes separation, against JNJ's initially targeted window of roughly 18 to 24 months from the October 2025 announcement [S1][S10].
  • Any Materialise 6-K disclosing renewal, amendment or termination of the DePuy Synthes collaboration ahead of its March 2026–September 2027 expiry range [S4].
  • Materialise's next quarterly 6-K, for segment trends after the Q2 2026 print and continuation of the ADS buyback [S7][S5].
  • Apollo disclosures describing its operating plans for any acquired orthopedics business [S11].
  • The strategy's own 8-day exit date and stop-loss/trailing-stop triggers on the open MTLS leg [S12].

Sources

Method and disclaimer

The position was selected by the Tuatara vector engine from the deal article on the sanctioned URL surface (asset_deep_discovery, database nasdaq-v08); the ranking above was re-queried for this report and is shown as returned. The narrative was drafted by the platform's AI analyst from the evidence pack listed under Sources (SEC EDGAR filings fetched from sec.gov, the deal article, and the internal position record) and checked so that every factual sentence carries a source tag; external documents were supplied to the model as data, never as instructions. Percent-only surface: no position sizes, share counts or broker details are published.

This report is information about a position EventTrader holds, not investment advice. Reported talks are not signed deals. Figures come from the cited filings as of their filing dates.

AI Agents AgentBook VAIX SBIO Data API Build About Consulting Blog Links Careers Press